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Clinical trials are being conducted to evaluate the safety and
efﬁcacy of hematopoietic stem cell transplantation (HSCT) as a
therapy for patients with severe, refractory systemic lupus ery-
thematosus (SLE). Nurses coordinating the care of patients receiv-
ing HSCT may be unfamiliar with aggressive systemic autoim-
mune diseases, such as refractory SLE. The presentations of SLE
can include nephrotoxicity, pulmonary toxicity, permanent alter-
ations in mobility, cognitive impairment, blindness, chronic pain,
as well as the many complications of long term immunosuppressive
therapy. Such problems present intense and unanticipated chal-
lenges for the medical team and affect many aspects of a patient’s
physical and emotional well being.
The purpose of this project is to share our experience using a
nurse led Collaborative Care Model. The model highlights impli-
cations for the multidisciplinary care team, nursing education and
support, and resource utilization. It also provides a template for
utilizing patient resources not previously identiﬁed.
Complex and serious problems are an inherent part of SLE and
present different dynamics and chronicity when compared to typ-
ical hematology/oncology HSCT patients. Therefore, a care man-
agement model promoting collaborative relationships within a
multidisciplinary team was essential. The nursing led team, which
included research nurses, clinical nurses, clinical nurse specialists,
nurse managers, and nurse practitioners, was instrumental in the
Collaborative Care Model.
At our research center, this model was utilized to coordinate the
HSCT care of 8 patients with severe SLE. The research nurse
functioned as team coordinator, maintaining constant communi-
cation between the patient, transplant team, rheumatology service
and other specialties involved in the plan of care. The research
nurse ensured protocol compliance, ongoing staff education and
protection of human subjects. Interdisciplinary meetings were held
weekly to provide a forum for discussion and dissemination of
information. The model facilitated a partnership between nurses,
medical specialists and ﬁnancial, social, and community services
which ensured timely access to resources and support.
As the role of HSCT is evaluated in additional non-malignant
disorders, nurses will be faced with new challenges and unfamiliar
patient populations. HSCT centers may ﬁnd our Collaborative
Care Model a way to effectively utilize resources and manage
complex patients.
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TREATMENT OF ACUTE GRAFT VS. HOST DISEASE AFTER UNRELATED
DONOR UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC
PATIENTS
Baker, E.J.2, Frey, M.A.2, Kurtzberg, J.2 1Duke University Hospital,
Durham, NC; 2The Duke Pediatric Blood and Marrow Transplant
Program, Durham, NC.
Unrelated donor umbilical cord blood (UCB) has been shown to
be an important source of hematopoietic stem cells for transplan-
tation in patients unable to ﬁnd a fully matched related or unre-
lated donor. UCB is readily available and can be used with partial
HLA matching allowing access to donors for transplantation for
the many patients who will never ﬁnd or who do not have time to
ﬁnd a perfectly matched bone marrow donor. Over the past 13
years, our program has performed 600 UCBT in pediatric pa-
tients with hematological malignancies, bone marrow failure syn-
dromes, immunodeﬁciency syndromes, hemoglobinopathies and
inborn errors of metabolism. In two thirds of these transplants,
donor/recipient pairs were matched at 4/6 HLA loci. Grades II-IV
acute graft-versus-host disease (GvHD) occured in approximately
35-40% of patients underdoing UCBT despite prophylactic ther-
apy. We have utilized cyclosporine/methylprednisolone or, more
recently cyclosporine/cellcept (MMF) for GvHD prophylaxis.
Many patients experience erythroderma with fever between days
11-25 post transplant, before neutrophil engraftment which may
represent engraftment syndrome or early GvHD. We have treated
this syndrome with a pulse of methylprednisolone (500mg/m2/
dose IV q12h X 4 doses for patients receiving conventional dose
steroids for GvHD prophylaxis, or 1-2mg/kg/day divided BID for
those on MMF). Responding patients taper steroids over the next
few weeks. Those that don’t respond or who experience rash or
diarrhea after initial steroid taper clearly have acute GvHD and are
switched to FK-506 with dacluzimab. Most patients are controlled
on this regimen which is then slowly weaned over the next 3-4
months. For the small number of patients (5%) not responding
to this therapy, inﬂiximab is added. For those failing inﬂiximab,
alternative therapies are pursued. GvHD after UCBT is different
than that after bone marrow transplantation in that rashes are
milder and progression to the GI tract is rarer and more indolent.
Liver GvHD is rare. This presentation will discuss the clinical
presentations, treatment and overall outcomes of pediatric patients
undergoing UCBT developing acute GvHD.
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OUTCOMES OF PEDIATRIC PATIENTS TRANSPLANTED A SECOND TIME
AFTER EXPERIENCING GRAFT FAILURE WITH UNRELATED DONOR
UMBILICAL CORD BLOOD TRANSPLANTATION
Baker, J.H.1, Martin, P.L.1, Driscoll, T.1, Szabolcs, P.1, Allison, J.1,
Gurganus, K.1, Ciocci, G.1, Parikh, S.1, Prasad, V.1, Kurtzberg, J.1
1Duke University Medical Center, Durham, NC.
Approximately 20% of patients undergoing unrelated donor um-
bilical cord blood transplantation (UCBT) with a single cord blood
unit, will fail to engraft. The causes for graft failure include host
immunological rejection with or without autologous reconstitu-
tion, infection and relapse. Over the past 13 years, the Pediatric
Blood and Marrow Transplant Program at Duke has transplanted
600 Pediatric patients with malignant diagnoses, lysosomal stor-
age diseases, hemoglobinopathies, congenital marrow failure syn-
dromes and congenital immunodeﬁciency syndromes with unre-
lated donor UCB. Thirty of these patients have experienced graft
failure and have been treated with a second UCBT as salvage
therapy. Median age of the group was 5 years (range 1-20 years),
73% were male, 40% non-Caucasian and 43% had malignant
diagnoses. All but 2 patients received myeloablative therapy as
preparation for their ﬁrst transplant. The median cell dose for the
ﬁrst transplant was 4.410e7/kg (range 0.99-21.25). 60% of the
ﬁrst transplants were matched at 4/6 HLA loci while 32% were
matched at 5/6 loci. Reasons for graft failure after transplant #1
were persistent leukemic disease (n1), autologous recovery
(n12) and graft rejection with aplasia (n17). All patients were
prepared for their second transplant with reduced intensity therapy
including cyclosphosphamide 30mg/kg/dose daily x 2, ATG (horse
or rabbit) x 3 days /- ﬂudarabine, campath or low dose TBI. Cell
doses were similar to the ﬁrst transplant and HLA disparity slightly
greater. All patients were supported with G-CSF mobilized, irra-
diated granulocytes during their second aplasia. Twenty patients
(66%) engrafted with donor cells after a second (n18) or third
(n2) transplant. Two patients died before engraftment, 1 re-
mained in relapse, and the others experienced second autologous
reconstitution. Eleven patients (35%) remain durably engrafted,
surviving long term with a median follow-up of 2 years (range
1-7 years). We conclude that a second UCBT after primary graft
failure offers a chance for long term survival in a signiﬁcant num-
ber of patients.
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AN EXPLORATORY ANALYSIS OF SYMPTOM EXPERIENCE AT DAYS 30
AND 100 FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT)
Bevans, M.F.1, Mitchell, S.A.1, Marden, S.1 1Clinical Center, National
Institutes of Health, Bethesda, MD.
Background: Despite advances in AHSCT treatment and sup-
portive care, post-transplant complications are common and char-
acterization of patients’ symptom experience is needed before de-
veloping symptom management strategies. Purpose: Using the
Symptom Management Model1 as a theoretical foundation, this
exploratory analysis examined patients’ symptom perception and
symptom evaluation in the early period following AHSCT.Meth-
ods: Data were collected as part of a prospective study examining
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health-related quality of life in AHSCT patients. The Symptom
Distress Scale (SDS) was used to identify 11 treatment-related
symptoms and the associated degree of distress. Patients’ rated
each symptom on days 30 and 100 following AHSCT with 1
indicating no awareness of a change from normal to 5, the highest
degree of discomfort. Symptom perception was a rating of a symp-
tom as  2 on the SDS; symptom evaluation was a rating of the
associated symptom distress as 2 (mild), 3 (moderate), or 4 -5
(severe). Symptoms were identiﬁed as forming groups when 3 or
more symptoms existed concurrently. Data were analyzed using
descriptive statistics and Pearson’s product-moment correlations.
Results: At day 30, patients (N67) were mostly male (69%), with
ECOG performance status 0 or 1 (82%) and a mean age of 40 years
(SD 13). Patients (n57) at day 100 were mostly male (63%),
with ECOG 0 or 1 (51%) and a mean age of 38 years (SD11). At
day 30, patients reported fatigue (90%) and appetite (79%) as the
most prevalent symptoms with appetite as the most distressing
(22%). At day 100, the most prevalent symptoms were fatigue
(81%) and appearance (60%) with fatigue as the most distressing
(11%). Several groups of co-existing symptoms were identiﬁed.
The largest group (fatigue, appetite, insomnia, bowel pattern) was
identiﬁed in 30 (45%) patients at day 30 with a signiﬁcant (p0.01)
correlation (r.50) between appetite and bowel pattern. A smaller,
prevalent group (fatigue, bowel pattern, insomnia) was identiﬁed in
17 (30%) patients at day 100 with signiﬁcant (p0.05) correlations
between: insomnia and fatigue (r.50); and insomnia and bowel
patterns (r.50). Conclusion: At a time of transitioning from
hospital discharge to the home community, patients perceive mul-
tiple symptoms with appetite (day 30) and fatigue (day 100) as
severely distressing. Symptoms coexist concurrently to form sev-
eral groups and within the larger groups, few relationships exist
between symptoms.
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FLY ME TO THE MOON
Caraher, R.3, Ahmed, S.3, Frey, M.A.3, Jordan, L.E.3, Kurtzberg, J.3
1Duke University Hospital, Durham, NC; 2The Duke Pediatric Blood
and Marrow Transplant Family Support Program, Durham, NC; 3The
Duke Pediatric Blood and Marrow Transplant Program, Durham, NC.
The care of the pediatric patient undergoing blood and marrow
transplantation is complex and intense. Patients undergoing this
type of treatment are often critically ill and many will succumb to
their treatment or disease. Patients are often hospitalized for
months and parents/caregivers are required to stay with them for
the duration of the hospitalization. The stress and burden on both
the caregiver and the nursing staff is immense. Numerous studies
have now focused on caregiver burnout and compassion fatigue of
staff caring for these children. Burnout and turnover rates of staff
are often much higher than the National average. The Duke
Pediatric Blood and Marrow Program has developed several pro-
grams to support caregivers and staff working in this environment.
The team adheres to a primary nursing model. The primary nurs-
ing team provides continuity and consistency for both the child and
family. Additional components for our support program include a
Family Support Program and a highly trained social worker staff.
The purpose of this abstract is to present the Duke Pediatric Blood
and Marrow “Fly Me To The Moon Program”. This program was
developed to supplement existing programs that support the emo-
tional and psychosocial needs of the patient and nursing staff. The
program incorporates basic principles including bereavement ac-
tivities, nursing retention strategies and caregiver support. The
goals of the program are to reduce caregiver stress and burnout and
to support nurses caring for these patients. The presentation will be
introduced with a slide show and music, speciﬁc tools and activities
used in the program will then be discussed.
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NURSING INITIATIVES TO ADDRESS ETHICAL DILEMMAS ON A BLOOD
AND MARROW TRANSPLANT (BMT) UNIT
Causton, C.A.1, Johnston, P.A.1, Neumann, J.L.1, Slieper, C.1 1MD
Anderson Cancer Center, Houston, TX.
Ethical issues and questions are a consistent aspect of caring for
Blood & Marrow Transplant (BMT) patients. The complexity of
the treatment and potential side effects are ongoing challenges.
The advancement of BMT speciﬁc treatments with new and cut-
ting edge protocols that expand our patient selection criteria, while
exciting and challenging, present nursing staff with constant ethical
questions.
On our BMT unit, monthly Nursing Ethics rounds are pre-
sented. Both night shift and day shift participate in rounds that
include the Institutional Clinical Ethicist, and BMT Program Di-
rector, a registered nurse who functions also as an adjunct ethicist
throughout the institution. A discussion topic is assigned each
month. An associated article is forwarded to all staff prior to rounds
to read as background. This is an educational opportunity for the
nursing staff to increase their knowledge of ethical principles and
dilemmas as well as an opportunity to discuss their concerns about
individual patients.
Another avenue for nursing staff to address ethical issues is
through monthly long term multidisciplinary rounds that focus on
BMT patients with extended length of stays. The multidisciplinary
group consists of the Clinical Ethicist, social worker, chaplain,
physical and occupational therapy, case management and nursing.
The bedside nurse presents the individual patient to the group.
Patients for discussion are chosen by established criteria and all
aspects of their progress and care are discussed. Many issues are
raised with resolution strategies addressed with the medical team.
Frequently in this venue, ethical concerns are discussed as the
broad picture is presented.
Both of these initiatives are venues organized by nurses and
provide the opportunity to discuss ethical issues of concern in
caring for a complex patient population as well as to establish
realistic future goals.
Multiple resources are used to select patients for discussion at
long term multidisciplinary rounds. To illustrate the methodology
used, a case study will be presented indicating the patient care
problems, concerns and suggestions by the multidisciplinary group
with patient outcomes. A list of topics discussed at monthly Nurs-
ing Ethics rounds will be presented showing the educational con-
tent that is presented to nursing staff.
381
PROPHYLACTIC USE OF HIGH CONCENTRATION FLUORIDE RINSE IN
THE HEMATOPOIETIC CELL TRANSPLANT PATIENT: PROMISING PO-
TENTIAL FOR DECREASING ORAL MUCOSITIS
East, K.A.1,2, Oholendt, M.S.1,2, Kamble, R.1,3, Carrum, G.1,3,
Bross, A.2 1Center for Cell and Gene Therapy, Houston, TX; 2The
Methodist Hospital, Houston, TX; 3Baylor College of Medicine, Houston,
TX.
Transplant nursing brings with it a host of patient issues includ-
ing but not limited to clinical, social, emotional, and ﬁnancial. As
transplant nurses it is our responsibility to provide our patients
with the best care available. One of the most impacting complica-
tions in the hematopoietic cell transplant (HCT) patient is oral
mucositis. Oral mucositis brings with it signiﬁcant effects on the
patient’s clinical course such as pain, anorexia, dysguesia, insomnia,
and infection.
Background/Purpose: Our department’s standard for oral care
in the HCT patient included a 0.4% ﬂuoride toothpaste (Gel-
KamTM) and 0.9% saline mouth rinse every 2 hours while awake.
Beginning in November of 2005 we initiated the use of a high
concentration ﬂuoride rinse (MEDOralTM) daily in addition to our
standard regimen. We noticed over a period of months a decrease
in the severity of oral mucositis. Retrospectively, we looked at
twenty-ﬁve (14 autologous and 11 allogeneic) patients to evaluate
the addition of MEDOralTM. Patients conditioning regimens var-
ied and included agents known to increase risk of mucositis. A
preliminary evaluation showed twelve of the twenty-ﬁve patients
had evidence of oral mucositis, grade I-II. Though there appears to
be a decrease in the severity/frequency of oral mucositis in these
patients, all twelve required some type of patient controlled anal-
gesia for grade III-IV esophagitis. These ﬁndings indicate that the
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